01—Abstract
Summary
Summary of the 10-K filed June 27, 2017. Cited figures are marked; the original filing is the authoritative source.
Medtronic plc's (MDT) 2017 10-K filing reveals a company focused on innovation and global expansion, underscored by its significant $50 billiona acquisition of Covidien in January 2015.
This strategic move has reshaped Medtronic's operational structure into four key groups: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The company reported net sales of $29.7 billionb for fiscal year 2017, indicating a 3% increase over the previous year. Growth was observed across most segments, driven by new product launches and strategic acquisitions like HeartWare and Smith & Nephew's gynecology business.
Medtronic continues to invest heavily in Research and Development, spending $2.2 billionc in fiscal year 2017, reflecting its commitment to therapy innovation. Financially, Medtronic demonstrated resilience with net income attributable to Medtronic of $4.0 billion for FY2017. The company's liquidity remains robust, supported by a strong balance sheet and substantial cash flow from operations.
Medtronic is actively managing its capital structure, including debt repurchases and share buybacks, signaling a focus on shareholder value. The company is also navigating a complex regulatory landscape, with ongoing efforts to ensure compliance and manage potential impacts from evolving healthcare policies and legal proceedings.
An important development during the fiscal year was the announcement of the planned divestiture of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses for $6.1 billiond, aimed at streamlining operations and focusing on higher-growth areas. This strategic divestiture, alongside continued investment in core therapeutic areas, positions Medtronic for future growth.
02—Key points
Key Highlights
- Medtronic completed the acquisition of Covidien for $50 billion, integrating its operations into four primary reporting segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes.
- The company reported net sales of $29.7 billion for fiscal year 2017, a 3% increase year-over-year, driven by new product introductions and strategic acquisitions.
- Research and Development expenses remained substantial at $2.2 billion in FY2017, highlighting Medtronic's commitment to innovation.
- Net income attributable to Medtronic was $4.0 billion for FY2017, with diluted earnings per share of $2.89.
- Medtronic announced plans to divest its Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses for $6.1 billion, aiming to refine its portfolio.
- The company maintained a strong liquidity position, with $13.7 billion in cash, cash equivalents, and current investments as of April 28, 2017.
- Medtronic continued to repurchase shares under its authorized programs, demonstrating a commitment to returning capital to shareholders.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2017, Medtronic plc kept $0.14.
- Revenue$29.71B100.0%
- Cost of revenue−$9.29B31.3%
- Gross profit$20.42B68.7%
- Operating costs−$15.04B50.6%
- Operating income$5.38B18.1%
- Interest, other & tax−$1.35B4.6%
- Net income$4.03B13.6%
Where FY2017 revenue went
$29.71B- SG&A: $10.02B, 34% of revenue
- Cost of revenue: $9.29B, 31% of revenue
- Other operating costs: $5.01B, 17% of revenue
- Net income: $4.03B, 14% of revenue
- Interest, other & tax: $1.35B, 4.6% of revenue
Kept 14% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2017filed June 27, 2017Financial Statements
FY2017 against FY2016
| Line item | FY2017FY2016 | Change |
|---|---|---|
| Revenue | $29.71B$28.83B | +3.0% |
| Cost of Revenue | $9.29B$9.14B | +1.7% |
| Gross Profit | $20.42B$19.69B | +3.7% |
| SG&A Expenses | $10.02B$9.47B | +5.8% |
| Operating Income | $5.38B$5.36B | +0.4% |
| Interest Expense | $1.09B$1.39B | −21.1% |
| Net Income | $4.03B$3.54B | +13.8% |
| EPS (Basic) | $2.92$2.51 | +16.3% |
| EPS (Diluted) | $2.89$2.48 | +16.5% |
| Shares Outstanding (Basic) | 1.38B1.41B | −2.2% |
| Shares Outstanding (Diluted) | 1.39B1.43B | −2.4% |
05—Questions
Frequently Asked Questions
What are Medtronic's main business segments and their contributions to revenue?
Medtronic operates through four main segments: Cardiac and Vascular Group (generating $10.5 billion in FY2017), Minimally Invasive Therapies Group ($9.9 billion in FY2017), Restorative Therapies Group ($7.4 billion in FY2017), and Diabetes Group ($1.9 billion in FY2017). These segments cover a wide range of medical technologies and solutions.
How did the Covidien acquisition impact Medtronic's financial performance and strategy?
The $50 billion acquisition of Covidien in January 2015 significantly expanded Medtronic's scale and product portfolio. It led to a reorganization into four new operating segments, provided increased financial strength, and is expected to accelerate Medtronic's strategies in therapy innovation, globalization, and economic value. The integration has also involved significant restructuring charges and acquisition-related expenses.
What is Medtronic's approach to Research and Development (R&D) and capital allocation?
Medtronic demonstrates a strong commitment to R&D, investing $2.2 billion in FY2017 (7.4% of net sales). The company focuses on therapy innovation, expanding access to care, and optimizing healthcare costs. Medtronic also actively manages its capital structure through debt repurchases and share buybacks, aiming to enhance shareholder value.
Are there any significant divestitures or strategic shifts mentioned in the filing?
Yes, Medtronic announced in April 2017 an agreement to sell its Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses for $6.1 billion. This move is intended to allow Medtronic to focus on higher-growth and higher-margin opportunities.
What are the key risks and challenges facing Medtronic according to this filing?
Medtronic faces several risks, including intense competition, reliance on patent protection, potential supply chain disruptions, increasing regulatory scrutiny and compliance costs, product liability claims, and the complexities of integrating acquired businesses. The company also notes risks associated with its international operations, currency fluctuations, and potential changes in healthcare reimbursement policies.
06—Continue